ACADIA Pharmaceuticals Inc. (BMV:ACAD)
Mexico · Delayed Price · Currency is MXN | Market Cap | 81.18B +8.4% |
| Revenue (ttm) | 19.90B +11.8% |
| Net Income | 6.65B +71.3% |
| EPS | 38.54 +66.4% |
| Shares Out | n/a |
| PE Ratio | 12.21 |
| Forward PE | 32.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 81 |
| Open | 499.00 |
| Previous Close | 515.00 |
| Day's Range | 499.00 - 499.00 |
| 52-Week Range | 362.00 - 517.11 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting sy... [Read more]
Financial Performance
In 2025, ACADIA Pharmaceuticals's revenue was $1.07 billion, an increase of 11.87% compared to the previous year's $957.80 million. Earnings were $391.00 million, an increase of 72.66%.
Financial numbers in USD Financial StatementsNews
Acadia Pharmaceuticals price target raised to $38 from $37 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $38 from $37 and keeps a Buy rating on the shares.
Acadia Pharmaceuticals price target raised to $28 from $27 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $28 from $27 and keeps an Equal Weight rating on the shares after the European Commission has granted…
Acadia Pharmaceuticals price target raised to $40 from $39 at Citi
Citi raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $40 from $39 and keeps a Buy rating on the shares ahead of the Phase 2 Alzheimer’s disease psychosis…
Acadia Pharmaceuticals announces EC marketing authorization for Daybu
Acadia Pharmaceuticals (ACAD) announced that the European Commission, or EC, has granted marketing authorization for Daybu for the treatment of neurobehavioral symptoms of Rett syndrome in adults and ...
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment o...
Acadia Pharmaceuticals price target raised to $49 from $45 at UBS
UBS raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $49 from $45 and keeps a Buy rating on the shares. Acadia is viewed favorably ahead of remlifanserin’s first…
Acadia Pharmaceuticals price target raised to $41 from $38 at Needham
Needham analyst Ami Fadia raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $41 from $38 and keeps a Buy rating on the shares. The firm is seeing an…
ACADIA Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference
NUPLAZID and DAYBUE continue to grow through education, expanded sales, and new formulations, with DAYBUE STIX rapidly gaining market share. European expansion is underway, and the pipeline, led by remlifanserin for Alzheimer's psychosis, targets large unmet needs.
Acadia Pharmaceuticals price target raised to $27 from $26 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $27 from $26 and keeps an Equal Weight rating on the shares.
Acadia Pharmaceuticals price target raised to $39 from $35 at Citi
Citi raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $39 from $35 and keeps a Buy rating on the shares.
Acadia Pharmaceuticals price target raised to $31 from $30 at BofA
BofA raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $31 from $30 and keeps a Buy rating on the shares. Following the Q2 report, the firm raised its…
Acadia Pharmaceuticals price target raised to $25 from $23 at Oppenheimer
Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $25 from $23 and keeps a Perform rating on the shares. The firm notes the company reported Q2 results…
Acadia Pharmaceuticals price target raised to $37 from $36 at RBC Capital
RBC Capital raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $36 and keeps an Outperform rating on the shares. Acadia delivered a strong update with Daybue…
Acadia Pharmaceuticals price target raised to $36 from $35 at Mizuho
Mizuho analyst Uy Ear raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $35 and keeps an Outperform rating on the shares.
Acadia Pharmaceuticals price target raised to $36 from $35 at Citizens
Citizens analyst Jason Butler raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $35 and keeps an Outperform rating on the shares. Acadia posted a strong Q2…
Acadia Pharmaceuticals reports Q2 EPS 18c, consensus 4c
Reports revenue $308M, consensus $295.52M. “Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growt...
ACADIA Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw 17% revenue growth to $308M, driven by DAYBUE (30% growth) and NUPLAZID (10% growth). DAYBUE STIX adoption accelerated, leading to raised guidance and a positive CHMP opinion in Europe. Strong cash reserves and pipeline progress, especially for remlifanserin, support future growth.
ACADIA Pharmaceuticals Slides: Q2 2026
ACADIA Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
ACADIA Pharmaceuticals Earnings release: Q2 2026
ACADIA Pharmaceuticals released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
ACADIA Pharmaceuticals Quarterly report: Q2 2026
ACADIA Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 4, 2026.
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. “Acadia delivered an outstanding second quarte...
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, Augu...
Acadia Pharmaceuticals price target raised to $36 from $34 at BMO Capital
BMO Capital transferred its coverage on Acadia Pharmaceuticals (ACAD) to who raised the firm’s price target to $36 from $34 and keeps an Outperform rating on the shares. The analyst…
Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $25 from $24 and keeps a Hold rating on the shares. While the firm thinks Acadia…
Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $25 from $24 and keeps a Hold rating on the shares. Stifel believes Acadia has given…